NCT04644107

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to Marizomib.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 19, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

November 25, 2020

Completed
Last Updated

November 25, 2020

Status Verified

November 1, 2020

First QC Date

November 19, 2020

Last Update Submit

November 19, 2020

Conditions

Solid Tumor

Keywords

Expanded AccessCompassionate Use

Interventions

MarizomibDRUG

Marizomib will be administered via IV

Also known as: CC-92763

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bristol Myers Squibb

Summit, New Jersey, 07901, United States

Location

MeSH Terms

Interventions

marizomib

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 19, 2020

First Posted

November 25, 2020

Last Updated

November 25, 2020

Record last verified: 2020-11

Locations

US(1)